Sorrento Says FDA Authorized Phase 1 Trial in Multiple Myeloma

By Michael Dabaie

Sorrento Therapeutics Inc. said the U.S. Food and Drug Administration authorized it to start a Phase 1 clinical trial of its anti-CD38 Dimeric Antigen Receptor-T Cell therapy for relapsed or refractory multiple myeloma.

The proprietary CD38 DAR-T cell therapy candidate demonstrated strong cytotoxic activity in preclinical studies, the company said.

Sorrento said the DAR-T technology is readily adaptable to dozens of cancer targets.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

08-02-21 0946ET